The effects of 4 weeks oral administration of omega-3 fatty acids on hepatic steatosis and insulin sensitivity in morbidly obese patients undergoing gastric bypass surgery.
Recruiting
- Conditions
- fatty livernon-alcoholic fatty liver disease100184241001965410017998
- Registration Number
- NL-OMON36714
- Lead Sponsor
- Academisch Medisch Centrum
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 20
Inclusion Criteria
MRS suggesting NAFLD
18-65 years of age
Morbid obesity
Ability to provide informed consent.
Stable weight 2 months prior to inclusion
Exclusion Criteria
Use of lipid lowering drugs (i.e., statins and fibrate drugs)
Any medical condition execpt for hypertension, dyslipidemia, glucose intolerance, treated hypothyroidism, coagulation disorders (increased bleeding time PT, aPTT)
Excessive alcohol intake - > > 14 units/week
Contraindications to MR scanning - pacemaker or metallic foreign body, claustrophobia etc.
Use of n-3 PUFA supplements within the prior 4 months,
Pregnancy, females who are breastfeeding.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>1. To assess the effects of omega-3 fatty acids on hepatic steatosis<br /><br>2. To assess the effects of omega-3 fatty acids on hepatic and peripheral<br /><br>insulin resistance</p><br>
- Secondary Outcome Measures
Name Time Method <p>1. Liver volume (hoe meet je die?)<br /><br>2. Fatty acids in the basal state and during hyperinsulinemia<br /><br>3. Plasma lipid profile<br /><br>4. Hepatic lipid profile<br /><br>5. Resting energy expenditure (REE)<br /><br>6. Differences in expression profiles in liver tissue<br /><br>7. Histological classification of hepatic steatosis<br /><br>8. changes in circulating inflammatory proteins</p><br>